Table 2.
Outcome- 28th day mortality [Yes = 1 vs. No = 0].
| Outcome- 28-day mortality – [Yes = 1 vs. No = 0] | ||
|---|---|---|
| Variables | Adjusted- odds ratio (95% CI) | P-value |
| Group – non-IMV | Ref | Ref |
| IMV | 8.78 [1.09–70.85] | 0.04 |
| Hypertension [Yes vs. No] | 0.32 [0.03–3.05] | 0.32 |
| Diabetes mellitus II [Yes vs. No] | 0.79 [0.1–6.02] | 0.82 |
| Congestive heart failure [Yes vs. No] | 1.31 [0.08–21.33] | 0.85 |
| Hypersensitivity lung disease [Yes vs. No] | 0.86 [0.04–17.36] | 0.92 |
| ESRD – End-stage renal disease [Yes vs. No] | 3.14 [0.3–32.57] | 0.34 |
| ARB [Yes vs. No] | 2.98 [0.08–106.99] | 0.55 |
| Remdesivir [Yes vs. No] | 1 [0.09–10.68] | 1 |
| Tocilizumab [Yes vs. No] | 0.85 [0.02–37.15] | 0.93 |
| BMI | 0.98 [0.83–1.16] | 0.8 |
The multivariable analysis showed that patients who required IMV had an approximately ninefold higher likelihood of dying within 28 days compared with those who did not require IMV (adjusted odds ratio [aOR] = 8.78; 95% CI, 1.09–70.85; p = 0.04).